The purpose of the study is to see how this treatment affects the cancer at the biological level. The study will give the medicines over repeated treatment cycles and follow how the cancer and body change over time. Samples and scans may be collected during the study to learn more about the cancer, and the treatment will be watched for side effects and other safety issues.

Prifetrastat (PF-07248144) is a new medicine that blocks a protein called KAT6, which may help slow cancer growth. ctDNA is small pieces of cancer-related DNA found in the blood, and the study will look at changes in this material to better understand the treatment’s effect. The study also includes analysis of cancer tissue and blood to learn more about how the medicines work.

Zanidatamab is given through a vein, while tucatinib and capecitabine are taken by mouth. Eribulin mesylate is also given through a vein. The study begins with a small part where the treatment doses are worked out and checked for safety. After that, more people receive the chosen treatment plan for a longer time. During the study, the cancer and any side effects are watched over time, and treatment may continue as long as it is helping and is tolerated.

Some people may also receive medicines used to help with symptoms or side effects, such as diphenhydramine hydrochloride, loperamide hydrochloride, paracetamol, hydrocortisone sodium succinate, dexamethasone sodium phosphate, and capecitabine or eribulin mesylate depending on the treatment group. A CT scan, which is a type of body image test, may be used during the study to look at the cancer. The study is planned to run from 2026 to 2028.

The purpose of the study is to evaluate how effective imlunestrant is compared to these standard treatments in preventing the return of breast cancer in patients who have already received two to five years of standard endocrine therapy. Endocrine therapy is a treatment that helps to stop or slow the growth of cancer by blocking the body’s natural hormones. Participants in the study will be randomly assigned to receive either imlunestrant or one of the standard treatments. The study will monitor participants over a period of time to see how well the treatments work in preventing cancer from coming back.

Throughout the study, participants will receive regular check-ups and assessments to monitor their health and the effectiveness of the treatment. The study aims to provide valuable information on whether imlunestrant can offer a better option for patients with this type of breast cancer, potentially improving outcomes and reducing the risk of cancer recurrence. The study will also look at the overall health and quality of life of participants while they are receiving treatment.

The purpose of the study is to evaluate the effectiveness and safety of the CBD oral solution over a period of 12 weeks. Participants will be randomly assigned to receive either the CBD solution or a placebo, and neither the participants nor the researchers will know which treatment each participant is receiving. This is known as a double-blind study. The study will follow a 2×2 crossover design, meaning that participants will switch treatments halfway through the study. This allows researchers to compare the effects of both treatments within the same group of participants. The main goal is to see if there is a significant reduction in joint pain, as measured by a tool called the Brief Pain Inventory.

Throughout the study, participants will be monitored for any changes in their joint pain, as well as other factors such as stiffness and overall joint function. The study will also assess the impact of the treatment on participants’ quality of life, anxiety, and depression levels. Safety will be closely monitored, with attention to any side effects that may occur. The study aims to provide valuable information on whether CBD can be a helpful treatment for joint pain in patients undergoing AI therapy for early breast cancer.

The investigation uses a specialized technique known as PET, which is a type of scan used to visualize how certain substances work inside the body. During the process, the substance [68Ga]BED003 is administered through an intravenous injection, meaning it is delivered directly into a vein. This substance is designed to target a specific protein found in certain tumor environments to help create clearer images. The scans are often combined with a computed tomography, which uses X-rays to create detailed pictures of the body’s internal structures.

Participants in the study will undergo imaging to see how well the new substance can identify cancer cells within the peritoneum, which is the thin layer of tissue that lines the inner wall of the abdomen and covers most of the organs. The study will monitor how the imaging agent behaves over time and check for any side effects. The goal is to determine if this new method can provide more accurate information about the presence and location of these cancers compared to standard medical practices.

The purpose of this study is to find out if romiplostim can help maintain platelet counts high enough to allow patients to receive their full chemotherapy doses on time without delays or reductions. The study will compare romiplostim with placebo to measure its effectiveness. Participants entering the study must have a platelet count at or below a certain level and must have at least three more cycles of chemotherapy planned. The chemotherapy cycles are given every 21 or 28 days depending on the specific treatment plan.

During the study, participants will receive either romiplostim or placebo as an injection under the skin while continuing their regular chemotherapy treatment. The study medication will be given for a treatment period lasting up to 12 weeks. Doctors will monitor platelet counts, track whether chemotherapy doses need to be changed due to low platelets, and watch for any bleeding problems or other side effects. Participants will continue to be followed for safety monitoring for up to 36 months to check for any long-term effects.

The study is divided into different phases. In the first phase, the study will test different doses of ONA-255 to find the lowest dose that has a biological effect and the highest dose that people can tolerate without serious side effects. In the next phase, the study will focus on finding the best dose to use for future studies in people with hormone receptor-positive, HER2-negative breast cancer and possibly in people with metastatic gastric or gastroesophageal junction cancer. In the final phase, the study will look at how many people respond to treatment with ONA-255 at the recommended dose. Throughout the study, doctors will monitor participants closely with physical examinations, blood tests, and imaging scans to check how the cancer is responding and to watch for any side effects.

The study will also collect blood samples to measure how the body processes ONA-255 and how long it stays in the body. Tissue samples from the cancer may be collected to study markers like FGFR4, HER2, and genetic changes such as ESR1, PIK3CA, TP53, and RB1 mutations to better understand how the treatment works. Some participants may also have their response measured using RECIST criteria, which is a standard way of measuring tumor size changes. The study may use placebo in some cases. Doctors will track how long the treatment works, how long people live without their cancer getting worse, and overall survival.

The purpose of this study is to find out if GDC-4198 is safe when given alone or together with giredestrant, and to compare how well GDC-4198 combined with giredestrant works against cancer compared to abemaciclib combined with giredestrant. The study will also look at how the body processes these medicines and how they affect the cancer. The study is divided into two stages. In the first stage, a small number of participants will receive GDC-4198 either alone or with giredestrant to check for safety and to understand how the body handles the medicine. In the second stage, a larger number of participants will be randomly assigned to receive either one of two different doses of GDC-4198 combined with giredestrant, or abemaciclib combined with giredestrant. Throughout the study, doctors will monitor participants closely with regular check-ups, blood tests, and scans to see how the cancer responds to treatment and to watch for any side effects.

During the study, doctors will measure several things to understand how well the treatments work and how safe they are. They will check how long it takes before the cancer starts growing again, whether the cancer shrinks or disappears, and how long any improvement lasts. They will also track any unwanted effects from the medicines, changes in vital signs like blood pressure and heart rate, and results from blood tests. The study will also measure the levels of the medicines in the blood at different times to understand how the body processes them. Some participants will receive GDC-4198 with and without food to see if eating affects how the medicine works. The study will continue for several years to gather enough information about the long-term effects of these treatments.

The purpose of this study is to see how well Disitamab Vedotin works against advanced breast cancer in different groups of patients based on their HER2 and hormone receptor levels, particularly in patients who have already received other HER2-targeted treatments like trastuzumab deruxtecan. The study will look at several groups including patients with HER2-positive breast cancer, patients with hormone receptor-positive and HER2-low breast cancer, patients with hormone receptor-positive and HER2-ultralow breast cancer, and patients with hormone receptor-negative and HER2-low breast cancer, which is also called triple-negative breast cancer.

During the study, patients will receive Disitamab Vedotin and doctors will monitor how the cancer responds to the treatment by checking if tumors shrink or stop growing. The study will also track how long any positive responses last, how long patients live without their cancer getting worse, and overall survival. Blood samples will be taken to measure how the medication moves through the body and whether the immune system develops a response to the medication. Doctors will carefully watch for any side effects and will record any health problems that occur during treatment, including whether any changes need to be made to the treatment plan because of these side effects.

The purpose of the study is to compare how well RLY-2608 combined with fulvestrant works compared to capivasertib combined with fulvestrant in controlling the cancer and preventing it from getting worse. During the study, patients will be randomly assigned to one of the two treatment groups. They will continue receiving their assigned treatment for as long as it is helping them and they are not experiencing unacceptable side effects. Regular check-ups will be done to see how the cancer is responding to treatment using imaging scans, and to monitor for any side effects. Blood samples will be taken to measure the amount of medicine in the body.

The study will also look at how long people live, how many people respond to treatment, how long the response lasts, and whether the cancer remains stable for a certain period. Information will be collected about any unwanted effects that occur, including their severity and how they relate to the study medicines. The study will also assess how the treatment affects quality of life by using questionnaires that ask about symptoms and daily activities. The study is expected to start enrolling people in December 2025 and is planned to continue until July 2028.

Patients in this study will receive zanidatamab on its own, without combining it with other cancer treatments. The medicine will be given regularly over a treatment period that can last up to 60 weeks. The doctors will check how the tumors respond to the treatment by doing regular scans and tests. Some patients in the study may have breast cancer or cancers of the stomach and food pipe area, and they may have received a specific type of HER2-targeted therapy before, which is a treatment that works against the HER2 protein. For other types of solid tumors, patients should not have had this type of treatment before.

During the study, doctors will monitor patients carefully to see if the treatment is working and to watch for any side effects. This includes checking heart function, blood tests to see how the liver and kidneys are working, and measuring the size of the tumors. Patients will also be asked about symptoms they experience using questionnaires. The study will look at how many patients see their tumors shrink, how long the treatment keeps working, and how long patients live. Blood samples will be taken to measure the amount of medicine in the body and to check if the body makes any reaction against the medicine.

The purpose of the study is to find out whether adding Inavolisib to the standard injection improves the time that cancer does not get worse, known as progression‑free survival. Participants who have already completed an initial course of treatment are randomly assigned, without knowing which group they are in, to continue receiving either the new pill plus the injection or the placebo pill plus the injection. Treatment is given regularly over several months, and doctors will monitor the participants with routine health checks, scans, and blood tests to see how the cancer behaves and to record any side effects. The study also looks at overall survival, how well the tumor responds, and quality of life during the treatment period.

The purpose of the study is to evaluate how well a new drug called tersolisib works when added to other treatments. The medications being studied include CDK4/6 inhibitors, such as palbociclib, ribociclib, or abemaciclib, and endocrine therapy, which includes drugs like anastrozole, exemestane, letrozole, or fulvestrant. Participants will receive combinations of these medicines to see if the addition of tersolisib improves the treatment of the disease.

The study is conducted in different stages. In the first part, the focus is on finding the best dose of the new medication. In the second part, the new drug is compared to a placebo. Participants will take these medications through oral tablets or injections as assigned. The study continues for as long as the treatment is effective and the side effects are manageable.

The purpose of the study is to evaluate the effectiveness and safety of a combination of three medications. One group will receive Inavolisib, Ribociclib, and Fulvestrant, while another group will receive a placebo along with Ribociclib and Fulvestrant. Inavolisib and Ribociclib are taken as pills, while Fulvestrant is given as an injection into the muscle.

Participants in the study will be assigned to one of the two treatment groups. Over the course of the study, the combination of drugs will be monitored to see how the cancer responds and to observe any side effects. The study will track how long the cancer stays stable and how long patients live while receiving these treatments.

Participants may receive elacestrant, which is a type of medication used to block the effects of hormones that help cancer grow. Some individuals might also be given ribociclib, a medication known as a CDK4/6 inhibitor that helps stop cancer cells from dividing. The treatments are administered as oral use tablets. Depending on the group assigned, some participants may receive these medications alone or in combination with other standard hormone therapies, and some may receive a placebo.

The study follows participants over a period of time to monitor how they respond to the different medication combinations. The process involves tracking long-term outcomes, such as overall survival, which is the length of time from the initial diagnosis until death, and disease-free survival, which measures the time during and after treatment that a person lives without any signs or symptoms of the cancer. The researchers will also look at how the treatments affect the quality of life and any side effects that may occur during the study period.

The treatment involves several different medications used as chemotherapy, which are drugs designed to kill fast-growing cancer cells. These drugs include paclitaxel, gemcitabine, carboplatin, and eribulin. Participants will receive these medications through an intravenous infusion, a process where medicine is delivered directly into a vein. Some participants will receive BNT327 along with the drugs, while others will receive the placebo along with the drugs. This is a double-blind study, meaning neither the participants nor the researchers know which specific treatment is being administered during the course of the trial.

During the study, researchers will monitor how long patients live and how long they remain stable without the cancer growing further. The study also tracks how well the tumors shrink or disappear in response to the medicine. Changes in the patient’s overall health and how they feel physically will also be observed to ensure the safety of the treatments provided.

Participants in the study will take silymarin in the form of a coated tablet. The study will observe how these medications affect liver enzymes, specifically AST and ALT, which are substances measured in the blood to check for liver irritation or damage. The period of observation for these changes will take place during the first six months of treatment.

The purpose of this study is to evaluate how well inavolisib works and how safe it is when given at two different dose levels in combination with fulvestrant. The study will look at whether the cancer shrinks or disappears in response to treatment, and will pay special attention to certain side effects that can happen with inavolisib, such as high blood sugar levels, mouth sores, and diarrhea. People in the study will be randomly assigned to receive either a 9 milligram dose or a 6 milligram dose of inavolisib each day, along with fulvestrant. The study is designed for people who have already received treatment with a combination of a type of medication called a cyclin-dependent kinase 4/6 inhibitor and hormone therapy, but whose cancer has continued to grow.

During the study, participants will receive their assigned treatment and will be monitored regularly to see how the cancer responds and to check for any side effects. The study will measure things like how many people have their cancer shrink, how long the cancer stays under control, and how long it takes for the cancer to respond to treatment. Participants will also be asked to report symptoms they experience through questionnaires to help understand how the treatment affects their daily life and well-being. The treatment can continue for up to two years, and the entire study is expected to last until mid-2028.

The purpose of this study is to find the best amount and timing of indocyanine green to create enough difference in brightness between the tumor and normal tissue, and to check whether this glowing effect can help surgeons accurately identify the edges of tumors during surgery. The study will look at how well the fluorescence imaging, which is a technique that uses special cameras to see the glowing substance, matches with what is found when tissue is examined under a microscope after removal. Researchers will also count how many additional glowing areas are found and confirmed to be cancer, as well as cases where the glow incorrectly suggests cancer when there is none or misses cancer that is present.

During the study, patients who are already planned to have surgery to remove their cancer will receive an infusion of indocyanine green before or during their operation. Surgeons will use special cameras that can detect the fluorescence to look at the tumor area and the surrounding tissue. The removed tissue and any lymph nodes will be examined both with the fluorescence camera and later under a microscope to compare the results. The study will measure the brightness difference between tumor and normal tissue, check whether the edges of the removed tissue are free of cancer cells, and record any side effects that occur. The goal is to determine if this imaging method can help surgeons remove cancer more completely while preserving healthy tissue.

The purpose of the study is to find out if 6QC-ICG is safe and well-tolerated when applied to tissue, and whether it can help doctors see any remaining cancer cells during surgery. The study has two parts. Part A involves healthy volunteers who will have the substance applied to a small wound on their skin to check for any unwanted effects. Part B involves patients who have been diagnosed with a specific type of breast cancer and are scheduled to have surgery. During their operation, the substance will be applied to the area where the tumor was removed to see if it lights up any remaining cancer cells that might need to be taken out.

Throughout the study, researchers will carefully monitor participants for any side effects or problems. They will check vital signs like blood pressure and heart rate, take blood and urine samples for laboratory tests, and perform heart rhythm tests using an ECG. For the patients having surgery, doctors will take pictures using special cameras that can see the fluorescent signal from the imaging agent, and they will compare these images with laboratory results from tissue samples to see how well the substance works at identifying cancer cells.

The purpose of this study is to find out how many people in each treatment group have no remaining cancer or only a small amount in the breast and nearby lymph nodes after receiving the study treatment and before having surgery. The study will also look at how safe these treatments are, what side effects they may cause, and how they affect the body. Additionally, the study will examine whether participants are able to have surgery as planned and will follow participants over time to check if the cancer comes back and how long they survive.

Participants in this study will be randomly assigned to one of the treatment groups and will receive the study medicines for several months before having surgery to remove the cancer. During the study, participants will have regular visits where doctors will perform examinations, take blood samples, and do heart tests to check how the treatment is working and monitor for any side effects. Participants will also be asked to complete questionnaires about how they are feeling and any symptoms they may be experiencing. After surgery, participants will continue to be followed to see how well the treatment worked and to monitor their overall health.

The purpose of the study is to find the best dose of BNT323 when used together with BNT327, to check if these treatments are safe, and to see if they help patients with advanced breast cancer. The study is divided into two parts. In the first part, different doses of BNT323 combined with BNT327 will be tested to find the recommended dose for further testing. In the second part, the effectiveness and safety of BNT323 alone, BNT327 alone, and the combination of both treatments will be compared to see how well they work in shrinking or controlling the cancer.

During the study, patients will receive the assigned treatment and will be monitored for any side effects and for how their cancer responds to the treatment. The study will measure things like whether the tumors shrink or disappear, how long any response to treatment lasts, and whether the disease remains stable. Patients will need to have tumors that can be measured and will undergo heart function tests before starting treatment to ensure their heart is working properly. The study will track various safety measures including any unwanted effects from the treatments, whether treatment doses need to be changed or stopped, and overall how well patients tolerate the medications.

The purpose of this study is to find out if magnesium sulfate works as well as dexmedetomidine when added to ropivacaine for pain control after mastectomy surgery. The study will measure how long the pain relief lasts by recording the time between when a patient wakes up from anesthesia and when they first ask for additional pain medicine. Patients in the study will receive general anesthesia for their surgery, and they will also receive a nerve block called an erector spinae plane block. This type of block is given by injecting the pain medicine near the muscles along the spine in the back. Some patients will receive ropivacaine with magnesium sulfate added, while others will receive ropivacaine with dexmedetomidine added.

During the study, doctors will watch how well the pain control works and check for any side effects. They will ask patients to rate their pain level at different times after surgery using a scale from zero to ten, where zero means no pain and ten means the worst pain imaginable. They will also keep track of how much additional pain medicine patients need in the first twenty-four hours after surgery. The study will monitor heart rate and blood pressure, and watch for side effects such as nausea, vomiting, slow heart rate, low blood pressure, breathing problems, itching, or any problems related to the nerve block itself. At the end, patients will be asked how satisfied they are with their pain control using a scale from zero to one hundred.

The purpose of this study is to see how well Datopotamab deruxtecan works in stopping the cancer from getting worse, which is measured by looking at how long patients live without their cancer progressing. The study will also look at how safe the medication is by checking for side effects such as mouth sores, eye problems, and other serious reactions. Patients in this study will receive the study medication and will be monitored regularly to see how their cancer responds to treatment and to check for any side effects. The study will also measure how many patients have their cancer shrink or stay the same size, how long any positive response to treatment lasts, and how long patients survive after starting the treatment.

During the study, doctors will take images and samples to track how the cancer is responding to the medication. The study is designed for patients whose cancer has a specific pattern of hormone receptors and HER2 levels, and who are not suitable candidates for another similar medication. Patients will need to have a certain level of general health and organ function to participate, and their cancer must be measurable or visible on scans. The study will continue for several years to collect information about how well the treatment works over time.

The purpose of this study is to collect detailed information about lung structure and function before and after radiotherapy treatment. By comparing images taken before treatment starts with images taken after treatment is completed, researchers want to see what changes happen in the lungs as a result of the radiotherapy. These changes will be looked at by examining ventilation maps, which are special images that show how air moves through different parts of the lungs. The study aims to identify areas where the lung function may have improved or worsened due to the radiation treatment.

During the study, participants will undergo scanning sessions where they will breathe in the xenon and oxygen gas mixture while lying in the CT scanner. The scans will capture images of the lungs while the gas is present, allowing doctors to see which areas of the lungs are receiving good airflow and which areas may not be working as well. Participants will need to hold their breath for short periods of about three seconds during the scanning. The study will involve scans done before the radiotherapy begins and again after the radiotherapy treatment has finished, so that doctors can measure and compare any changes that have occurred in lung function and tissue structure.

The main purpose of this research is to understand how quickly tamoxifen becomes effective in the body and how it affects certain markers in the tumor tissue. The study will investigate whether a shorter treatment period of three weeks can be as effective as the standard twelve-week treatment period. During the study, participants will receive tamoxifen tablets daily, with a maximum daily dose of 40 mg.

The research involves taking small samples of tumor tissue to measure a protein called Ki67, which helps determine how fast cancer cells are growing. The study will also measure levels of endoxifen (a substance that tamoxifen is converted into in the body) and monitor how the treatment affects hormone levels in the blood. Participants will be asked to complete questionnaires about their symptoms and overall well-being during the treatment period.

The treatment will involve taking PF-07248144 tablets by mouth along with fulvestrant injections into the muscle. Some patients will receive this combination, while others will receive different standard treatments such as everolimus or exemestane. The purpose is to determine if the combination of PF-07248144 and fulvestrant works better than currently available treatments in stopping the cancer from growing.

The study will last for up to 24 months. During this time, patients will have regular check-ups to monitor their health and see how well the treatment is working. Doctors will use special scans to measure if tumors are shrinking, staying the same size, or growing. They will also keep track of any side effects that patients may experience during the treatment.

The main purpose of this research is to determine if izalontamab brengitecan works better than standard chemotherapy treatments in patients who cannot receive certain types of immunotherapy treatments (anti-PD1/PD-L1). The study will measure how long patients live without their cancer getting worse and their overall survival time. During treatment, some patients may also receive pegfilgrastim, a supportive care medicine that helps the body make white blood cells.

The medications will be given in different ways – some through an intravenous infusion directly into a vein, while others, like capecitabine, are taken by mouth as tablets. The study will continue for several years to gather information about how well the treatments work and how safe they are for patients.

The purpose of this study is to provide continued access to ribociclib treatment for patients who have been receiving this medication in previous Novartis-sponsored studies and have shown benefit from the treatment. The study will monitor how well patients tolerate the treatment over an extended period and track any side effects that may occur.

During the study, patients will continue their current treatment combination that includes ribociclib. The medications are given by mouth as tablets or capsules, except for goserelin acetate which is given as an implant. Patients will have regular check-ups to monitor their health and any potential side effects throughout their participation in the study.

The purpose of this research is to test how safe bemarituzumab is and how well it works in treating different types of solid tumors. The study is divided into two parts. In the first part, doctors will closely monitor how patients respond to the medication and any side effects that may occur. In the second part, they will evaluate how effective the medication is at fighting the cancer.

During the study, patients will receive bemarituzumab through regular infusions. The doctors will track the progress of the treatment using different medical tests and imaging scans such as computed tomography (CT) or magnetic resonance imaging (MRI). They will monitor how the tumors respond to the treatment and keep track of any changes in the patient’s health throughout the study period.

The purpose of this research is to evaluate how patient education and personalized coaching affect how long patients continue their treatment with ribociclib. The study will examine different approaches to supporting patients through their treatment journey and measure how these approaches impact treatment continuation.

During the study, participants will take ribociclib tablets daily and receive specialized coaching support. Throughout the treatment period, which lasts up to 36 months, patients will complete questionnaires about their quality of life and overall well-being. They will also keep a diary to track any breaks in their treatment. The study will monitor how patients manage their treatment and any side effects that may occur.

The main purpose is to determine if using elacestrant by itself for 4 weeks before surgery is as effective as using it in combination with leuprorelin. The effectiveness will be measured by examining changes in a protein called Ki67, which indicates how fast cancer cells are growing. During the study, patients will receive either elacestrant tablets alone or elacestrant tablets plus leuprorelin injections.

Throughout the treatment period, patients will undergo various assessments including blood tests and magnetic resonance imaging (MRI) scans. The study will monitor how well patients respond to treatment and track any side effects they may experience. After the treatment period, patients will proceed with their planned breast surgery, and follow-up evaluations will continue for up to 6 months after surgery.

The study will test MK-5684 alongside several other medications that may be used as standard treatments, including tamoxifen, exemestane, letrozole, fulvestrant, megestrol, and medroxyprogesterone. Some participants may also receive medications to manage side effects, such as dexamethasone, hydrocortisone, and fludrocortisone.

During the study, participants will receive either MK-5684 or standard treatment medications. The study will track how long participants live without their cancer getting worse, their overall survival time, and how well they respond to treatment. Doctors will monitor participants for any side effects throughout the treatment period, which may last up to 60 months.

The main goal of this research is to understand the long-term safety of GD2IL18CART treatment. The study will follow patients who have already received this treatment to monitor how they respond over time. During the study, doctors will track any delayed side effects that might occur, including the possibility of infections, cancer returning, or new health problems developing.

The study involves regular check-ups to monitor patients’ health status. For younger patients, growth and development will also be monitored. The research team will collect information about the patients’ overall health and perform tests to check if the treatment cells are still present in their bodies. This long-term monitoring will help understand how the treatment affects patients over time.

The study will test a new drug called inavolisib (also known as GDC-0077) in combination with other medications including letrozole and ribociclib. These medications are given as tablets that patients take by mouth. The treatment is given before surgery, which is known as neoadjuvant treatment, to see if it can help shrink the tumor.

The main purpose of this study is to understand how safe these drug combinations are and how well patients can tolerate them. During the study, patients will receive treatment for up to 6 months. Doctors will monitor patients’ health through regular check-ups and laboratory tests. They will also examine how well the treatment works by measuring changes in the tumor and checking for any side effects that patients may experience.

The study involves several medications that target HER2-positive breast cancer. Patients will receive trastuzumab emtansine (also known as T-DM1) as treatment. Before starting treatment, patients will undergo imaging with a specially modified version of trastuzumab that has been labeled with a radioactive substance to help create detailed images of the cancer. This imaging helps doctors understand how the cancer might respond to treatment.

During the study, patients will receive regular medical check-ups to monitor their response to treatment. The research team will track how long the treatment remains effective and watch for any side effects. They will also collect tissue and blood samples to study how the cancer cells change over time. This information will help doctors better understand which patients are most likely to benefit from specific treatments.

The purpose of the study is to see if Denosumab can reduce the risk of developing any type of breast cancer, including invasive breast cancer or a condition called DCIS (ductal carcinoma in situ), which is an early form of breast cancer. Participants in the study will receive either Denosumab or a placebo, and the study will compare the outcomes between these two groups. The study will also look at other health outcomes, such as the time it takes for any breast cancer to develop, the occurrence of other types of cancer, and the frequency of breast biopsies.

The study will take place over several years, with participants receiving regular injections and undergoing health assessments to monitor for any signs of breast cancer or other health changes. The goal is to gather information that could lead to new ways to prevent breast cancer in women with the BRCA1 mutation.

The purpose of the study is to see if trastuzumab deruxtecan can better delay the progression of the disease compared to the current standard treatment. Participants in the study will be randomly assigned to receive either trastuzumab deruxtecan or the combination of CDK4/6 inhibitors and endocrine therapy. The study will monitor the participants over a period to assess how long the treatments can keep the cancer from getting worse. The study will also look at the overall safety and any side effects of the treatments.

Participants will receive their assigned treatment and will be regularly monitored by healthcare professionals. The study will involve various assessments, including imaging tests like MRI or CT scans, to track the cancer’s response to the treatment. The study is expected to continue until 2029, with recruitment starting in 2025. This research is important for understanding how to better treat this specific type of breast cancer and improve outcomes for patients in the future.

Participants in the study will receive the treatment and be monitored over a period of time to observe any changes in their condition. The study aims to measure the response of the cancer to the treatment, looking for signs of improvement or stability. The treatment will be given in cycles, and the health of the participants will be closely watched by the study team to ensure safety and to gather information on how the treatment affects the cancer.

The study will also collect data on any side effects experienced by participants, as well as other health indicators such as laboratory test results and vital signs. This information will help researchers understand the overall impact of zelenectide pevedotin on patients with NECTIN4 Amplified Advanced Breast Cancer and contribute to the development of new treatment options for this disease.

The purpose of this study is to evaluate the safety and effectiveness of the combination of capivasertib and fulvestrant in patients whose cancer has progressed despite previous hormone-based treatments. Participants in the study will receive these medications and will be monitored to assess how long they can continue the treatment before needing to switch to another therapy. The study will also look at how this treatment affects the quality of life of the participants.

Throughout the study, participants will take the medications orally and will be regularly assessed by healthcare professionals. The study aims to provide insights into how well this combination of treatments works in managing advanced breast cancer and improving the time patients can stay on treatment. The trial will also explore the impact of the treatment on patients’ daily lives and overall well-being.